Expression of estrogen and progesterone receptors in human ductal invasive breast carcinoma not otherwise specified: Is there any difference between premenopausal and postmenopausal women?

Acta Clinica Croatica

Volumn 50, Issue 2, 2011, Pages 169-175

  Petricevic, Joško ^a   Petkovic, Marija ^b   Jonjic, Nives ^c  

^a UNIVERSITY OF MOSTAR   (Bosnia and Herzegovina)

^b KBC RIJEKA   (Croatia)

^c UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

Carcinoma, ductal, breast; Postmenopause; Premenopause; Receptors, estrogen; Receptors, progesterone

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; POSTMENOPAUSE; PREMENOPAUSE; PROTEIN EXPRESSION; TISSUE DIFFERENTIATION; BREAST TUMOR; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84856597530     PISSN: 03539466     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. HARRIS JR, LIPPMAN ME, MORROW M, HELL-MAN S. Disease of the breast. Philadelphia-New York: Lip- pincott-Raven, 1996.
2. ELSTON CW, ELLIS IO, GOULDING H, PINDER SE. The breast. 3rd ed. New York: Churchill Livingstone, 1998.
3. CLEMONS M, GOSS P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85.
4. SPEIRS V, WALKER RA. New perspectives into the bio- logical and clinical relevance of oestrogen receptors in the hu- man breast. J Pathol 2007;211:499-506.
5. SANCHEZ R, NGUYEN D, ROCHA W, WHITE JH, MADER S. Diversity in the mechanisms of gene regulation by estrogen receptors. Bioassays 2002;24:244-54.
6. American Joint Committee on Cancer (AJCC): AJCC cancer staging manual. 5th ed. Philadelphia, PA: Lippincott-Raven, 1997.
7. CLARK GM, McGUIRE WL. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 1988;15:20-5.
8. MINK D, von TONGELEN B, VILLENA-HEINSEN C, HEISS C, SCHMIDT W. Breast cancer and prognostic fac- tors. Tumor size, degree of differentiation, proliferation ki- netics and expression of hormone receptors. Eur J Gynaecol Oncol 1994;15:424-36.
9. HLUPIC L, JAKIC-RAZUMOVIC J, BOŽIKOV J, CORIC M, BELEV B, VRBANEC D. Prognostic value of different factors in breast carcinoma. Tumori 2004;90:112-9.
10. OSBORNE CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998;51:227-38.
11. FREUND A, CHAUVEAU C, BROUILLET JP, LUCAS A, LACROIX M, LICZNAR A, et al. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 2003;22:256-65.
12. ALLRED DC, HARVEY JM, BERARDO M, CLARK GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
13. PUJOJ P, DAURES JP, THEZENAS S, GUILLEUX F, ROUANET P, GRENIER J. Changing estrogen and pro- gesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer 1998;83:698-705.
14. ASHBA J, TRAISH M. Estrogen and progesterone receptor concentrations and prevalence of tumor hormonal phenotypes in older breast cancer patients. Cancer Detect Prev 1999;23:238-44.
15. ALMASRI NM, Al HAMAD M. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res 2005;7:598-604.
16. HARVEY JM, CLARK GM, OSBORNE CK, ALLRED DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
17. MENASCE LP, WHITE GR, HARRISON CJ, BOYLE JM. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and simple post-FISH binding technique. Genomics 1993;17:263-5.
18. ENMARK E, PELTO-HUIKKO M, GRANDIEN K, LAGERKRANTZ S, LAGERKRANTZ J, FRIED G, et al. Human estrogen receptor beta gene structure, chromo- somal localization and expression pattern. J Clin Endocrinol Metab 1997;82:4258-65.
19. SHOKER BS, JARVIS C, SIBSON DR, WALKER C, SLOANE JP. Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 1999;188:237-44.
20. SHOKER BS, JARVIS C, CLARKE RB, ANDERSON E, HEWLETT J, DAVIES MP, et al. Estrogen receptor-posi- tive proliferating cells in the normal and precancerous breast. Am J Pathol 1999;155:1811-5.
21. CALANDRA RS, CHARREAU EU, ROYER de GIAR? OLI M, BALDI A. Incidence of estrogen, progesterone and prolactin receptors in human breast cancer. Prog Clin Biol Res 1984;142:97-108.
22. DONTU G, El-ASHRY D, WICHA MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 2004;15:193-7.
23. ALLRED DC, BROWN P, MEDINA D. The origins of es- trogen receptor alpha-positive and estrogen receptor-negative human breast cancer. Breast Cancer Res 2004;6:240-5.
24. ANDERSON WF, CHU KC, CHATTRERJEE N, BRAWLEY O, BRINTON LA. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol 2001;19:18-27.
25. GRUVBERGER S, RINGER M, CHEN Y, PANAVALLY S, SAAL LH, BORG A, FERNO M, PETERSON C, MELTZER PS. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001;61:5979-84.
26. BARDOU VJ, ARPINO G, ELLEDGE RM OSBORNE CK, CLARK GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer data bases. J Clin Oncol 2003;21:1973-9.
27. HORWITZ KB, McGUIRE WL. Estrogen control of progesterone in human breast cancer. J Biol Chem 1978;253:2223- 38.
28. HOPP TA, WEISS HL, HILSENBECK SG, CUI Y, ALLRED DC, HORWITZ KB, et al. Breast cancer patients with progesterone receptor A PR-A rich tumors have poorer disease- free survival rates. Clin Cancer Res 2004;10:2751-60.
29. SPEIRS V, MALONE C, WALTON DS, KERIN MJ, ATKIN SL. Increased expression of estrogen receptor ß mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 1999;59:5421-4.
30. PALMIERI C, LAM EW, MANSI J, CHENG G, SUNTERS A, O'HARE MJ, et al. The expression of ER ßcx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 2004;10:2421-8.